Hansen Dang

Hansen Dang

Auto-generated profile, based on publicly available information

Hansen Dang

Department of Ophthalmology and Visual Sciences, Carver College of Medicine, University of Iowa Hospitals & Clinics, Iowa City, Iowa

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2019 in Hepatology
Verified
Journal Article
Closed access
PDF file
HDHansen Dang
Hansen Dang
YYYee Hui Yeo
Yee Hui Yeo
SYSatoshi Yasuda
Satoshi Yasuda
CHChung-Feng Huang
Chung-Feng Huang
EIEtsuko Iio
Etsuko Iio
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen

6 April 2018 in Cancer
Verified
Journal Article
Open access
PDF file
NKNathan G. Kim
Nathan G. Kim
PNPauline P. Nguyen
Pauline P. Nguyen
HDHansen Dang
Hansen Dang
RKRadhika Kumari
Radhika Kumari
GGGabriel Garcia
Gabriel Garcia
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the few cancers whose incidence continues to increase. The goal of the current study was to investigate the presentation and survival trends of patients with HCC presenting to a university hospital between 1998 and 2015.METHODS: Study data were ascertained by individual chart review with survival data also supplemented by National Death Index query up to December 31, 2015. Patients were divided into three 6‐year groups by diagnosis date (1998‐2003, 2004‐2009, and 2010‐2015).RESULTS: A total of 2106 consecutive patients with HCC were included. The majority of patients had either hepatitis C (56.7%) or hepatitis B (22.1%), but cases of nonalcoholic steatohepatitis HCC increased by 68% over the most recent time period. Screening/surveillance identified 61% of HCC cases, but only 31% of these patients underwent curative treatment, which did not increase significantly over time. The overall median survival was 29.8 months (2.48 years) and without improvement over time. On multivariable analysis, Asian or Hispanic ethnicity, meeting Milan criteria, and receiving any of the standard HCC treatments were found to be significantly associated with improved survival, but diagnosis time period and liver disease etiology were not.CONCLUSIONS: Over the last 18 years, the percentage of cases of nonalcoholic steatohepatitis HCC has increased but not overall survival. It is interesting to note that only 31% of patients with HCC identified via screening/surveillance received any curative treatment. Further research is needed to better understand the barriers to curative care for patients with HCC and the causes of the lack of improvement in survival in the more recent patient cohort. Cancer 2018;124:2588‐98. © 2018 American Cancer Society.

24 May 2018 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
VCVincent Chen
Vincent Chen
MYM.‐L. Yeh
M.‐L. Yeh
ALA. K. Le
A. K. Le
MJM. Jun
M. Jun
WSW. K. Saeed
W. K. Saeed
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen
Summary: Background: Hepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC) worldwide. It remains incompletely understood in the real world how anti‐viral therapy affects survival after HCC diagnosis.Methods: This was an international multicentre cohort study of 2518 HBV‐related HCC cases diagnosed between 2000 and 2015. Cox proportional hazards models were utilised to estimate hazard ratios (HR) with 95% (CI) for anti‐viral therapy and cirrhosis on patients' risk of death.Results: Approximately, 48% of patients received anti‐viral therapy at any time, but only 17% were on therapy at HCC diagnosis (38% at US centres, 11% at Asian centres). Anti‐viral therapy would have been indicated for >60% of the patients not on anti‐viral therapy based on American criteria. Patients with cirrhosis had lower 5‐year survival (34% vs 46%; P < 0.001) while patients receiving anti‐viral therapy had increased 5‐year survival compared to untreated patients (42% vs 25% with cirrhosis and 58% vs 36% without cirrhosis; P < 0.001 for both). Similar findings were seen for other patient subgroups by cancer stages and cancer treatment types. Anti‐viral therapy was associated with a decrease in risk of death, whether started before or after HCC diagnosis (adjusted HR 0.62 and 0.79, respectively; P < 0.001).Conclusions: Anti‐viral therapy improved overall survival in patients with HBV‐related HCC across cancer stages and treatment types but was underutilised at both US and Asia centres. Expanded use of anti‐viral therapy in HBV‐related HCC and better linkage‐to‐care for HBV patients are needed.

8 May 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AWAlina Wong
Alina Wong
ALAn Le
An Le
MLMei-Hsuan Lee
Mei-Hsuan Lee
YLYu-Ju Lin
Yu-Ju Lin
PNPauline Nguyen
Pauline Nguyen
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen
The effect of metabolic syndrome on chronic liver diseases other than non-alcoholic fatty liver disease has not been fully elucidated. Our goal was to evaluate if metabolic syndrome increased the risk of liver-related complications, specifically hepatocellular carcinoma (HCC) and decompensation, in cirrhotic chronic hepatitis C (CHC) patients. We conducted a retrospective cohort study of 3503 consecutive cirrhotic CHC patients seen at Stanford University from 1997–2015. HCC developed in 238 patients (8-year incidence 21%) and hepatic decompensation in 448 patients (8-year incidence 61%). The incidence of HCC and decompensation increased with Hispanic ethnicity, diabetes, and number of metabolic risk factors. Multivariate Cox regression analysis demonstrated that, independent of HCV therapy and cure and other background risks, Hispanic ethnicity with ≥2 metabolic risk factors significantly increased the risk of HCC and hepatic decompensation. There was no interaction between Hispanic ethnicity and metabolic risk factors. All in all, metabolic risk factors significantly increase the risk of liver-related complications in cirrhotic CHC patients, especially HCC among Hispanics. As the prevalence of metabolic syndrome increases globally, targeted health interventions are needed to help curb the effects of metabolic syndrome in CHC patients.

1 April 2017 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
AKAlina Kutsenko
Alina Kutsenko
ALAn Le
An Le
HDHansen Dang
Hansen Dang
STSam Trinh
Sam Trinh
PNPauline Nguyen
Pauline Nguyen
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen

1 May 2018 in Gastroenterology
Verified
Journal Article
Closed access
VCVincent L. Chen
Vincent L. Chen
MYMing-Lun Yeh
Ming-Lun Yeh
JYJu Dong Yang
Ju Dong Yang
DPDebi Prasad
Debi Prasad
JGJennifer Guy
Jennifer Guy
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen